Study of Enfuvirtide in HIV-Positive Subjects

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Trimeris
• Collaborator: Hoffmann-La Roche
• Treatments: Enfuvirtide

Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-